Velphoro, a ferric citrate drug used to treat hyperphosphatemia in adults with chronic kidney disease on dialysis, is available.
When is Velphoro's Patent Expected to Expire?
The patent for Velphoro is expected to expire in 2026, based on the information available through DrugPatentWatch.com [1].
Who is Developing Velphoro?
Velphoro is developed by AstraZeneca [2].
What is Velphoro Used For?
Velphoro is prescribed to manage elevated phosphate levels in patients undergoing dialysis for chronic kidney disease. It works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [3].
What is the Mechanism of Action for Velphoro?
Velphoro contains ferric citrate, which dissociates in the gastrointestinal tract. The ferric iron then binds to dietary phosphate, forming insoluble ferric phosphate. This complex is then eliminated from the body in the feces, thereby reducing serum phosphate levels [3].
What are the Alternatives to Velphoro for Hyperphosphatemia?
Other phosphate binders used for hyperphosphatemia include calcium-based binders, sevelamer carbonate, and lanthanum carbonate [4]. Each has a different mechanism and potential side effect profile. For instance, calcium-based binders can lead to hypercalcemia and have been associated with vascular calcification [5]. Sevelamer and lanthanum are non-calcium, non-aluminum based binders [4].
What are the Potential Side Effects of Velphoro?
Common side effects associated with Velphoro include diarrhea, nausea, vomiting, constipation, and abdominal pain [2].
How is Velphoro Administered?
Velphoro is taken orally as a chewable tablet during meals [3]. The dosage is individualized based on serum phosphate levels [2].